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Western lifestyle is associated with a sustained low grade increase in inflammation -increased levels of endotoxin in
the body and increased activation of Toll-like receptors and neutrophils, which leads to impaired immunity and
reduced resistance to disease, changes which might explain the epidemic of chronic diseases spreading around the
globe. The immune system cannot function properly without access to bacteria and raw plants, rich not only in
bacteria but also in plant fibre, antioxidants, healthy fats and numerous other nutrients. Modern food technology
with plant breeding, separation, condensation of food ingredients, heating, freezing, drying, irradiation,
microwaving, are effective tool to counteract optimal immune function, and suspected to be a leading cause of so
called Western diseases. Supply of pre-, pro-, and synbiotics have sometimes proved to be effective tools to
counteract, especially acute diseases, but have often failed, especially in chronic diseases. Thousands of factors
contribute to unhealth and numerous alterations in life style and food habits are often needed, in order to prevent
and cure “treatment-resistant” chronic diseases. Such alterations include avoiding processed foods rich in pro-
inflammatory molecules, but also a focus on consuming substantial amounts of foods with documented anti-
inflammatory effects, often raw and fresh green vegetables and tubers such as turmeric/curcumin.Review
Introduction
Human life without access to plants and bacteria would
be miserable. Plants and bacteria, which have existed for
billions of years, have often robust protection system,
which can be used by humans. Our Palaeolithic
forefathers did on annual basis receive their daily food
from at least five hundred plants and also, as the food
they ate often were stored in the soil, a rich supply of
various microorganisms. The food of modern food is
based on nutrients received from only a small number of
plants; 80% of the nutrients come from 17 plants and
50% of the calories from eight grains. Furthermore, the
main part of Western foods is extensively processed;
growth enhancement, separation, condensing, drying,
freezing, irradiation, burning, microwaving, toasting,
adding various ingredients and especially heating. It is
well-known that some important plant ingredients start
disappearing already when heated above 28oC, important
plant enzymes and microbes above 42o C, dys-Correspondence: s.bengmark@ucl.ac.uk
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in any medium, provided the original work is pfunctioning proteins be added above 80oC and hetero-
cyclic amines and also trans-fatty acids from about
130oC, and increasing as the heating of the food
increases further, all changes being negative to human
health.
Among the dys-functioning proteins produced during
heating of foods are the so called Maillard products,
often referred to as advanced glycation and advanced
lipoxidation end products, and abbreviated as AGEs and
ALEs. Among foods rich in AGEs and ALEs are: dairy
products especially powder milk (frequently used in
enteral nutrition and baby formulas, as well as in numer-
ous foods such as ice cream), cheese, bakery products
(bread crusts, crisp breads, pretzels, biscotti) and cereals
(rice crispies), overheated (especially deep-fried and
oven-fried) meat and poultry but also fish, drinks like
coffee and coca cola, Asian sauces including Chinese soy
sause, balsamico products and smoked foods in general -
for further information, see Goldberg et al [1,2]. The
consumption of such foods, often main constituents in
fast foods, have increased dramatically in recent decades,
much in parallel to the endemic of chronic diseases.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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Numerous chemical substances, additives to foods
and pharmaceutical drugs, seem to derange the im-
mune system. It is clear, even if not fully investi-
gated, that a large number of chemicals, when
consumed, have a strong negative influence on the
immune system and the body’s resistance to disease.
In the past, priority was not given to investigate
eventual negative effects on the innate immune sys-
tems of consumed food additives and pharmaceutical
drugs. It has long been known that antibiotics sup-
press various immune functions, and especially
macrophage activities such as chemiluminescence re-
sponse, chemotactic motility, bactericidal and cyto-
static ability and similar negative effects have also
been seen with other commonly used drugs such as
H2-blockers, proton inhibitors and surface-protection
agents.
Several other factors increase the degree of systemic
inflammation in the body:
– Impaired hormonal homeostasis increases oxidative
stress/ release of free radicals, intracellular
accumulation of “waste products”, inhibits apoptosis,
disturbs repair mechanisms, reduces gene
polymorphism, increases premature shortening of
telomeres and reduces immune defence and
resistance to disease, changes often observed in
premature aging and in various several chronic
diseases [3].
– Low level in the body of vitamin D and subsequent
secondary hyperparathyroidism [4].
– Low levels in the body of antioxidants such as folic
acid and glutathione and increased levels of
homocysteine [5].
– High levels in the body of estrogens, especially 17β-
estradiol, often induced by high consumption of
hormone-rich dairy products [6].
– High levels of angiotensin/renin [7]
– Larger intake of glutenoids [8].
The reason why attempts to reduce inflammation
with the use of probiotics have in the past sometimes
failed might be that the pro-inflammatory pressure
induced by the underlying disease is simply too high,
but also influenced by larger consumption of proin-
flammatory foods and prescription drugs, many with
strong inflammation-enhancing abilities. It is likely that
in certain conditions additional measures are needed in
order to achieve successful treatment with probiotics.
Measures such as reduced supply of proinflammatory
foods, restriction in use of pharmaceuticals and a sig-
nificant increase in intake of such plant foods known to
be rich in anti-inflammatory vitamins and antioxidants,
especially might various polyphenols be needed - see
further below.Effects of plant fibres on systemic inflammation
It should be observed that various seeds, nuts, beans and
peas are especially rich in fibre, foods which no longer
are eaten in the quantities they deserve. A common
recommendation of minimum daily fibre intake is in the
range of, 30–35 g per day, which roughly corresponds to
about half a kg of fruits and vegetables, or, as often
expressed, 5 to 8 fresh fruits and vegetables per day. The
recommendations for children above the age of 2 y are
usually defined as age + 5 g/day. No precise recommen-
dation exists yet about intake of fibre under different
conditions of disease. The daily intake of dietary fibre is
unsatisfactory in all Western countries, especially among
people with low level of education and low income. In
the US for example, the estimated daily intake of fibre is
app 14–15 g/day or about 50% of what is recommended,
and far below the 60–80 g/d of substrate required to
maintain a large bowel flora of 1014 microorganisms,
known to be typical for a healthy and well-functioning
human colon. Most Americans and Europeans have lost
the ability to maintain a large proportion of what can be
regarded as a natural flora [9]. A study in a North-Euro-
pean population found Lactobacillus plantarum, Lacto-
bacillus rhamnosus and Lactobacillus paracasei ssp
paracasei on the rectal mucosa of healthy humans only
in 52%, 26% and 17% respectively [10]. The colonization
rate with other, commonly milk-born probiotic bacteria,
such Lactobacillus casei, Lactobacillus reuteri and Lacto-
bacillus acidophilus was in the same study only 2%, 2%
and 0% respectively.
Commonly consumed cooked roots and other starchy
vegetables, grains, consumed as bread, cereals and por-
ridge, but also most of the fruits, consumed in Western
countries, contain relatively little fibre, usually no more
than 1–3 g/serving. The largest amount of consumed
plant fibre is provided by resistant starch (rich in raw
tubers such as potato and in unripe green banana).
Cooked tubers, especially potatoes will re-crystallize
when allowed to cool after cooking. The daily consump-
tion of this type of fibre varies from one individual to an-
other with several hundred per cent (app 8–40 g/d). The
second largest source of fibre is non-starch polysacchar-
ides (app 8–18 g/d). The third group of fibre is oligosac-
charides (onions, artichoke, banana, cecoria), which
although important to health, regrettably today is con-
sumed in much too small quantities (app 2–8 g/d) [11].
Function of dietary fibres
Supplemented fibres are associated with several health
benefits. The best documented physiological effects, in
addition to providing energy and nutrients to the host
and flora, are that they:
 change in mucosal structure, increase mucosal
growth and improve mucosal function.
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reduce production of putrifactive gases and provide
resistance to invading microorganisms
 reduce serum triglycerides, serum cholesterol and
VLD lipoproteins
 reduce the glycemic response to eating
 improve water and electrolyte balance and increase
bioavailability and absorption of minerals such as Ca,
Mg Fe and Zn.
Consumption of medical fibres should always be
regarded as a surrogate for not consuming enough of
fresh fruits and vegetables. Generally processed fibers are
much less efficient in the body compared to natural
fibres. There is no solid information to support that sup-
plementation of medical fibres to healthy individuals eat-
ing a diet rich in fruits and vegetables is associated with
additional health benefits. Medical fibres are mainly
needed because the individual has lost the ability to con-
sume enough of fresh fruits and vegetables. This is often
the situation in persons with severe allergy, in old and
debilitated persons and in persons with some GI disor-
ders, such as short bowel syndrome and advanced diver-
ticular disease. This is also most often the condition for
critically ill patients, for whom enteral supply of concen-
trates of medical fibres has become a most valuable clin-
ical tool. It must, however, always be remembered that
bioactive fibres during the processing have lost their con-
tent of numerous important antioxidants and nutrients,
some of which when possible should be separately sup-
plemented, and whenever possible complemented by
supply of fresh fruits and vegetables.
Health benefits of increased plant fibre consumption
Significant information on beneficial effects from
increased intake of plant fibres and so called prebiotics
exists mainly for two large groups of diseases:
Blood glucose control/prevention of type 2 diabetes.
Fibre is a slow release system for delivery of glucose to
the body. Fibre, regularly supplied to patients with
diabetes will significantly reduce the level of blood
glucose and the need of insulin. Studies suggest that the
most pronounced effects of fibres on glycemic index are
obtained by water-soluble fibres. Guar-gum is in this
respect by far the most clinically tried fibre and will, as
based on 15 different studies, reduce blood glucose to
almost half (44%).
Lipid control/prevention of coronary heart disease.
Soluble fibres such as pectin, guar gum, betaglucans
(oat) reduce significantly blood cholesterol both in
hypercholesterolemic and normocholesterolemic
individuals, effects not found when non-soluble fibres
such as cellulose and wheat bran are tried. Soluble
fibres are excellent substrates for production in the
large intestine of short chain fatty acids (SCFAs),known prevent leaky gut and also to reduce the levels
of cholesterol/s.
A meta-analysis reports statistically significant protect-
ive effects against coronary heart disease in 14/16 studies
[12]. In addition, larger fibre consumption is also known
to reduce clotting and increase fibrinolysis, also import-
ant for prevention of arterial wall plaques and of throm-
bosis formation.
Clinical use of fibres
Substances, important to health: amino acids such as ar-
ginine, glutamine, histidine, taurine, various sulphur and
related amino acids, polyamines, omega-fatty acids, nu-
merous vitamins and antioxidants are all to a great ex-
tent supplied to the body from plants. One cannot
expect any significant amount of antioxidants to be
delivered to the lower level of the gastrointestinal tract,
if not carried by plant fibres. It is important to remember
that key nutrients such as omega-3 fatty acids, glutam-
ine, glutathione and several other nutrients are heat-sen-
sitive and do not tolerate processing or storage to any
larger extent. Plant fibres, which have been dried, heated
up or micro-waved cannot be expected to contain any
larger amounts of these, with this raw and unprocessed
foods are needed. It is highly desirable that, whenever
possible, the supply of commercial nutrition formulas
are complemented by supply of fresh fruit and vegetable
juices, as locally produced as ever possible. It is also de-
sirable that several different fibres are supplied in paral-
lel, and that both soluble and non-soluble fibres are
supplied. For example, oat fibres are mainly metabolized
in the proximal colon, while wheat fibres are known to
be effective in the distal part of the colon, e.g. the part of
colon where most cancers are localized. Oat has mainly
shown sepsis-reducing effects while wheat has mainly
been effective in cancer prevention.
Among the fibres commonly used in clinical nutrition
are:
Algal fibres. Most of the algal fibres are resistant to
hydrolysis by human endogenous digestive enzymes,
but are to various degrees fermented by colonic flora.
The soluble fibres consists in lamarans (a sort of β-
glucan associated with mannitol residues), fucans
(sulphated polymers associated with xylose, galactose
and glucoronic acid) and alginates (mannuronic and
guluronic acid polymers). The insoluble algal polymers
consist mainly in cellulose. Fermentation of alginates
yields high levels of acetate (80%), while lamirans yield
preferably butyrate (16%). It is most likely that algal
fibres will within a few years be routinely used in
clinical nutrition.
Fructans. Fructans starches and sucrose serve in the
plant as its energy reserve. These substances are also
produced by bacteria and fungi. Fructans are said to
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conditions and make it possible for the plants to survive
under harsh conditions, such as low temperature and
draft. The most well-known fructans are inulin (rich in
chicory, artichoke, onions, and banana) and phleins
(rich in various grasses). This far it is mainly inulin,
which has been tried in human nutrition. Various
oligosaccharides are reported to stimulate the flora and
especially the growth of Lactobacilli and Bifidobacteria
in the large intestine and to reduce the content of
potentially pathogenic microorganisms (PPMs) in the
intestine. Increase in the Bifidobacteria flora is regarded
as especially favourable as Bifidobacteria are known to
produce important vitamins, among them thiamine,
folic acid, nicotinic acid, pyridoxine and vitamin B12,
which is of great importance for health. A fructan
called neokestose, found in onion, is reported to have
even better ability than inulin to promote growth of
LAB. Also supplementation of fructans is reported to
reduce concentrations in serum of insulin, cholesterol
and triacylglycerol. It is also reported to promote
absorption of calcium and other minerals. Other
oligosaccharides such as those extracted from peas and
beans especially soya bean oligosaccharide (raffinose
and stachyose) and pyrodextrin, produced by pyrolysis
of maize and potato starch are also reported to be
beneficial for human health.
Glycomannans. Glycomannan, a glucose/mannose
polymer derived from a plant called Amorphophallus
konjak, which has several English names such as devil
tongue, elephant yam and umbrella arum. It has unique
hydroscopic abilities and will on contact with water
swell and form a viscous gel, which like other gels will
delay gastric emptying and intestinal transit time. It has
been shown to be effective in delaying absorption of
digestible energy. It has this far mainly been used in
Japan and other Asian countries to treat diabetes,
hypertension and hypercholesterolemia. Dietary supply
of konjak mannans has been shown in experimental
animals to alter the flora and reduce tumorigenesis. It is
also effective to control of diarrhoea in enteral
nutrition, especially in elderly patients, and to increase
the Bifidobacteria flora.
Oat gum. Oat contains a series of interesting
compounds, which is the reason why an increasing part
the world production of oat goes to the pharmaceutical
and cosmetic industries. The amino acid pattern of oat
is rather similar to that of human muscle (only that of
buckwheat is more alike), and can thus be expected to
deliver most of the amino acids needed to build
muscles. Oat is rich in water-soluble fibers, β-glucans,
and known for their antiseptic properties. Oat is also
rich in natural antioxidants, particularly ferulic acid,
caffeic acid, hydrocinnamic acid, and tocopherols andoat was before synthetic antioxidants were available
extensively used to preserve foods: milk, milk powder,
butter, ice-cream, fish, bacon, sausages and other food
products sensitive to fat oxidation. Another ingredient
richly available in oat is inositol hexaphosphate (phytic
acid), a strong antioxidant, particularly known to
enhance natural killer cell activity and to suppress
tumour growth. Oat is also rich in polyunsaturated fats/
polar lipids such as phosphatidylcholine, known for its
protective effects of mucosal and cellular surfaces.
Pectin. Also pectin is an interesting fibre, extensively
used by pharmaceutical and food industry. It has a
unique ability to form gels and is commonly used as a
carrier of pharmacologically active substances and is
common in baby foods. An important finding is that
pectin a very strong antioxidant against the three most
dominating oxidation damages induced by peroxyl-,
superoxide- and hydroxyl radicals. These effects might
explain why pectin has the capacity to stimulate the
gut-associated immune system and to prevent
disruption of the intestinal microflora. Pectins have
shown strong protective and healing effects on gastric
but also intestinal mucosa, in experimental studies not
inferior to what is observed with H2-blockers, proton
inhibitors and surface-protection agents [13,14]. Pectin
builds a protection layer in the stomach and facilitates
maintenance of gastric acidity, important for prevention
of colonization of the stomach by pathogens. Pectin is
also an excellent substrate for microbial fermentation.
Lactic acid bacteria key to fermentation of fibres
Not all fibres are easily fermented in the gut. Among the
more fermentation-resistant fibres are wheat fibres which
usually are not digested until they reach descending colon.
Also oligofructans (inulin or phleins) are difficult to ferment
and only a small minority of lactic acid bacteria (LAB) are
able to do so. When the ability of 712 different LAB to fer-
ment oligofructans was studied, only 16/712 were able to
ferment the phleins and 8/712 inulin [15]. Apart from
Lactobacillus plantarum only three other LAB species,
Lactobacillus paracasei subsp. paracasei, Lactobacillus bre-
vis and Pediococcus pentosaceus were able to ferment such
semi-resistant fibres. Another study investigated the ability
of 28 different LAB to ferment pure fructooligosacharides
(FOS). All Lb plantarum, Lb casei and Lb acidophilus
strains studied and most Bifidobacteria metabolized FOS,
in contrast to yoghurt bacteria such as Lb bulgaricus and
Streptococcus thermophilus and also Lactobacillus strain
GG, which all were unable to ferment these fibres [16].
Clinical experience with supplemented plant fibres
Plant fibres in constipation
Chronic constipation is one of the most common disor-
ders in Western countries. Its etiology remains despite
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studies unclear, but it is suggested high intake of dairy
products and intake of plant fibres play a significant role
in its pathogenesis. A randomized sample of 291 children
with idiopathic chronic constipation was in a case con-
trol study compared with 1602 healthy controls [17].
Constipation was clearly negatively correlated with low
intake of cellulose and pentose fibres (p< 0.001). Fructo-
oligosaccharides (FOS) may also have potential benefits
in constipation, since they exhibit many soluble dietary
fibre-like properties. In a study a total of fifty-six healthy
infants, age 16–46 weeks (mean age 32 weeks) were ran-
domly assigned to receive either 0.75 g FOS or placebo
added to a serving of cereals for 28 d [18]. The mean
number of stools per infant was 1.99 ± 0.62 per day in
the FOS-supplemented group compared with 1.58 ± 0.66
in the control group (P= 0.02).
Plant fibre to prevent and treat diarrhoea
In a large randomized study in acutely ill medical and
surgical patients, all requiring enteral nutrition for a
minimum of 5 days supplementation of hydrolyzed guar
gum was compared to a fibre-free enteral nutrition, the
incidence of diarrhoea being 9% with fibre-supplementa-
tion, compared to 32% with fibre-free nutrition (p> 0.05)
[19]. One of the effects of certain fibres is that it
increases the bioavailability and absorption of zinc,
which is especially shown for oligosaccharides. Zink sup-
plementation was in a randomized study in 3–59 months
children in Bangladesh proven effective to lower both
the incidence of diarrhoea and the duration of diarrhea
[20]. In another study from Bangladesh 250 g/L of green
(unripe) banana (eqv. to two fruits) or 2 g pectin/kg food
was compared to a supplemented rice diet in children
suffering from persistent diarrhoea [21]. The amounts of
and frequency of stools, the duration of diarrhoea, num-
bers of vomiting, use of oral rehydration and amounts iv
fluid solutions given were all significantly better reduced
in the the group supplemented green banana and pure
pectin. Recovery on third day was seen in 59% in the
green banana group, in 55% in the pectin group com-
pared to 15% in the rice only control group.
Plant fibre to support mineral absorption
It is well accepted that nutrition is of great importance
also for bone health. Most interest has this far focused
on calcium and vitamin D. Much less interest has been
paid to other important nutrients such as protein, and
especially to minerals such as phosphorus, potassium,
magnesium and vitamins such as C and K. Recent stud-
ies suggests that increased intake of plant fibers, fruits
and vegetables is associated with an increased bone min-
eral density also in elderly subjects, both women and
men [22,23]. Of all the many pure fibres available it ismainly the effects of oligosaccharides have been more
thoroughly studied, but so far mainly in experimental
animals Calcium absorption, bone calcium content, bone
mineral density, bone balance and bone formation/bone
absorption index are generally reported to be signifi-
cantly increased, and that as early already as after three
weeks of supplementation of a mixture of inulin and
fructooligosaccharides.
Plant fibre to control weight
No major effects on body weight by supplementation of
only prebiotic fibre have this far been reported. The
effects of dietary fibre on subjective hunger ratings and
weight losses were studied some twenty years ago in
members of a weight loss club. One hundred and eight
of 135 members completed the trial: 23 controls, 45 on
ispaghula granulate and 40 on bran sachets [24]. Both
fibre preparations reduced hunger at all meals. The mean
(±SD) weight reductions during the trial were
4.6 ± 2.7 kg for the controls, 4.2 ± 3.2 kg for the ispaghula
group and 4.6 ± 2.3 kg for the bran group (p> 0.05 for
both groups). Although supply of dietary fibre immedi-
ately before meals did reduce the feeling of hunger did it
not provide any additional benefits to the weight reduc-
tion. A more recent crossover study compared the effect
on satiety of supplementation of 27 ± 0.6 g/d of ferment-
able fibers (pectin, betaglucan) with similar amounts of
non-fermentable fibre (methylcellulose). The daily satiety
was significantly increased with non-fermentable
(methylcellulose) than with fermentable fibres (betaglu-
can, pectin) (p= 0.01) but no differences were observed
in daily energy intake or loss of body weight or body fat
[25].
Plant fibre in inflammatory bowel diseases (IBD)
Although both patients with IBD and irritable bowel syn-
drome (IBS) are known to under-consume dietary fibres,
there is little evidence that lack of dietary fibre plays a
role in the pathogenesis of these diseases. The ability of
maintaining remission in UC patients by a daily supply
of 10 g of Plantago ovata seeds (also called psyllium or
Ispaghula husk) was compared with daily treatment with
500 mg of mesalamine and a combination of the two
[26] Twelve months of treatment failed to demonstrate
any difference in clinical benefits between the three
groups. Germinated barley foodstuff (GBF), a by-product
from breweries, rich in hemi-cellulose and in glutamine,
was tried in 39 patients with mild-to-moderate active
UC [27]. Daily supply of 30 g reduced significantly the
disease activity, increased concentration of SCFAs, and
increased in stool the numbers of Bifidobacterium and
Eubacterium. It can well be that the observed effect were
more due to increased supply of glutamine and other
antioxidants such as various B vitamins than to the fibre
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products from breweries. Glutamine, as well as other
antioxidants, are known to attenuate pro-inflammatory
cytokines such as TNF-α and to enhance release of heat
shock proteins (HSP-72) [28].
A controlled study using oat bran as fibre source was
reported in a study of 22 patients and 10 controls, all
with quiescent UC. Daily supply during three months of
as much as 60 g of oat bran (eqv to 20 g dietary fibre)
resulted in a significant increase in faecal butyrate (aver-
age 36%), but also in significant reduction in abdominal
pain. All the treated patients tolerated well the large dose
of fibre and signs of relapse of disease were seen in none
of the colitis patients [29]. Butyrate has been shown to
inhibit NF-kB activation of lamina propria macrophages,
and to reduce the number of neutrophils in crypts and
surface epithelia, as well as the density of lamina propria
lymphocytes/plasma cells in patients with ulcerative col-
itis [30] - findings correlating well with the observed
decreased disease activity. Twenty patients with ileal
pouch-anal anastomosis received daily for two weeks
24 g of inulin. Significant reduction in inflammation was
observed at endoscopy and histology. In addition signifi-
cant increase in faecal concentrations of butyrate and
reductions in faecal pH, faecal content of secondary bile
acids, and growth of Bacteroides fragilis was observed
[31].
Plant fibre in irritable bowel disease
Dys-motility disorders are increasingly common in West-
ern Societies. Some evidence suggest that various dys-
motility disorders; gastroesophageal reflux problems, in-
fant colic and constipation are all food-related features,
and often due to intolerance to cow’s milk proteins [32].
Irritable bowel syndrome (IBS), is a clinical diagnosis
based on the occurrence of abdominal distension, ab-
dominal cramps, often increased transit time, more fre-
quent stools, and relief of pain on defecation. The
prevalence of the syndrome varies between and 7 and
22%, making IBS the most common functional gastro-in-
testinal disorder [33]. Unfortunately, no effective
pharmaceutical treatment exists, or when existing, is un-
acceptably toxic [34]. This has resulted in a need for
additional modalities for the treatment of IBS. Pre- and
probiotics appear in this perspective as attractive alterna-
tives, see further reviews [35,36] especially as early data
from human intervention studies but also results from
experimental studies in animals clearly demonstrate an
impact on the immune system: immune cells of the
GALT including Peyer’s patches [37]. However, a conse-
quence of feeding the currently favoured prebiotics (inu-
lin, fructo-oligosaccharides (FOS), trans-GOSs and
lactulose,) is increased gas production in the gut, which
might preclude prebiotic use where bloating or gas areprominent symptoms such as in diarrhoea-predominant
IBS, but might allow their mild laxative properties to be
useful in constipation-predominant IBS [38]. Over the
years some small open trials have been performed, but
this far, no larger and randomized trial has been
reported. However, a small open label trial with supple-
mentation of 15 g/day of a mixture of oligofructose
(70%) and inulin (30%) reported significant reduction in
disease activity (Harvey Bradshaw index fell from 9.8, SD
3.1 to 6.9 SD 3.4, p= 0.01) in parallel to a significant in-
crease in faecal bifidobacteria concentration (from 8.8,
SD 0.9 log 10 to 9.4, SD 0.9 log10 cells/g dry feces
p= 0.001). Also the IL-10 positive dendritic cells
increased (from 30 to 53% p= 0.06), and the percentage
of dendritic cells expressing TLR2 and TLR4 increased
from 1.7% to 36.8% p= 0.08, and from 3.6% to 75.4
p= 0.001) [38], respectively which offers hope for the
future.
Plant fibre in abdominal pain
Other dietary fibres have also been tried in various
groups of abdominal pain. A recent Cochrane review
was unable to find any evidence that fibre supplements,
lactose free diets or lactobacillus supplementation are ef-
fective in the management of children with recurrent ab-
dominal pain [39]. However, a study in adult patients
reports significant success with other fibres than classical
prebiotics. 188 adult IBS patients were classified as hav-
ing diarrhoea-predominant, constipation-predominant,
or changeable bowel habits type IBS and randomly
assigned to groups receiving 30 g/day of wheat bran or
5 g/day of guar gum (PHGG [40]. After four weeks,
patients were allowed to switch group, depending on
their subjective evaluation of their symptoms. Both fibre
and PHGG were effective in improving pain and bowel
habits. Significantly more patients switched from fibre to
PHGG (49.9%) than from PHGG to fibre (10.9%) at four
weeks. Intention-to-treat analysis showed a significantly
greater success in the PHGG group (60%) than in the
fibre group (40%). In addition, significantly more patients
in the PHGG group reported a greater subjective im-
provement than those in the fibre group. It was con-
cluded that improvements in core IBS symptoms were
observed with both bran and PHGG, but the latter was
better tolerated and preferred by patients [40].
Plant fibre to control infections . In an effort to prevent
nosocomial pneumonia and sepsis, patients with severe
multiple trauma were treated with beta 1–3 polyglucose
(glucan) - a component of cell walls of plants and
microbes [41]. Pneumonia occurred in 2/21 glucan-trea-
ted and in 11/20 patients in the control group (p< 0.01).
Infectious complications (pneumonia and/or general sep-
sis) occured in 14% of glucan-supplemented patients ver-
sus 65% in the control group (p< 0.001). Another study
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with fiber but also arginine, and antioxidants with a
standard high-protein formula in early enteral nutrition
in critically ill patients [42]. The supplemented group
had, in comparison to non-supplemented controls a
lower incidence of catheter-related sepsis (0.4 episodes/
1000 ICU days) than the control group (5.5 episodes/
1000 ICU days) ( p< .001), but no differences were
observed between the groups in incidence of ventilator-
associated pneumonia, surgical infection, bacteremia,
urinary tract infections, mortality and in long-term sur-
vival [42].
Pre- pro- and synbiotics improve innate immunity
Several plant fibres (prebiotics) and a few LABs (probio-
tics) have documented significant effects to improve both
the function of the innate immune system, the physical
barrier, and increase resistance to disease. The hope is
that combined supply of these components shall have
synergistic, e.g. more than additive effects in boosting
the immune system and enforcing the barrier functions.
Products which combine pre-and probiotics are called
synbiotics and treatments using the combination called
synbiotic treatment.
Choice strains for probiotic use
The choice of pre- and probiotics must be based on sci-
entific evidence. Stronger bioactivities cannot be
expected from LAB such as yogurt bacteria, chosen
mainly for their palatability. The strains to use must be
selected with care and based on extensive preclinical.
It is important to remember that the majority of LABs
have no or much limited effects on immune functions
and outcome. Constructing synbiotic formulations is es-
pecially demanding as most of the LAB used by industry
have no or limited ability to ferment bioactive fibres such
as inulin or phlein [15], no ability to adhere to human
mucus, low antioxidant capacity and most important, do
not survive the acidity of stomach and bile acid content.
It has been observed that strains that carry the same
name have different and sometimes opposing functions.
When the ability of 46 different Lactococcus lactis strains
to induce production of the cytokines interleukin (IL)-6,
IL- 12 and tumor necrosis factor (TNF)-α was studied, it
was clearly demonstrated that the extent of induction of
IL-6, IL-12 and TNF-α was cearly shown to be strain-
specific and not at all related to subspecies, bio-variety,
or the source of the isolate. The production of IL-6 var-
ied between 138 and 0 ng/ml IL-12 between 3 and 0 ng/
ml TNF-α between 20 and 0 ng/ml between various
strains carrying the same name [43].
Unfortunately few studies have looked at the synergis-
tic effects of simultaneous supply of LAB and fibres -
synbiotics. Natural foods supplies both LAB and a greatvariety of plant fibres. Combination of several fibres has
been shown to lead to additive effects on microbial eco-
system and immune responses [44], and multi-species
probiotics documented to be superior to single-species
probiotics, showing increased ability to enhance growth,
reduce antibiotic associated diarrhoea, prevent infections
(S typhimurium) and reduce pathogenic colonisation (E
coli) [45] Although some studies have used various syn-
biotic compositions, only two such compositions have
been produced after extensive preclinical studies:
1. An unistrain/unifibre composition, produced (Probi
AB, Lund Sweden) by fermentation of oat meal with
L. plantarum strain 299, containing 109 of LAB and
app 10 g oat fibre [46]. In a few studies a
commercial fruit juice, PRO VIVA™ containing 107 of
a related L. plantarum strain called 299 V,
(Skånemejerier, Malmö, Sweden) is also tried.
2. A multistrain/multifibre composition, called
Synbiotic 2000™, consisting in a mixture of 1010 and
a Synbiotic FORTE™ with 1011 of each of four LAB:
Pediacoccus pentosaceus 5–33:3, Leuconostoc
mesenteroides 32–77:1, Lactobacillus paracasei subsp
paracasei 19, and Lactobacillus plantarum 2362 and
2.5 g of each of the four fermentable fibres
(prebiotics): betaglucan, inulin, pectin and resistant
starch (Synbiotic AB, Höganäs, Sweden) [47,48].
Lund University microbiologists Åsa Ljungh and Tor-
kel Wadström developed this multi-strain/multi-fibre
synbiotic formula, which in recent years has been exten-
sively used in clinical trials. The choice of LAB for the
formulation was done after extensive studies of> 350
human [47] and >180 plant microbial strains [48] and
based especially the ability of the LAB to produce bio-
active proteins, transcribe NF-κB, produce pro- and anti-
inflammatory cytokines, produce antioxidants, and most
important, to functionally complement each other. In re-
cent studies both the Synbiotic 2000 FORTE™ but also a
Probiotic 2000 FORTE™ (no fibre added), containing 1011
of each of the four LAB, e.g. 400 billion LAB per dose
have been tried.
Plantarum, paracasei and pediococcus
When, as mentioned above, the ability of 712 different
LAB to ferment oligofructans was studied, only 16/712
were able to ferment semi-resistant fibred; the phleins
and 8/712 inulin; Lactobacillus plantarum, Lactobacillus
paracasei subsp. paracasei, Pediococcus pentosaceus and
Lactobacillus brevis and were able to ferment these
semi-resistant fibres [15]. Interesting clinical results are
also often obtained when these LAB are involved. When
more than 100 LAB were compared Lb paracasei subsp
paracasei were demonstrated to be the strongest inducer
of Th1 & repressor of Th2 cytokines [49]. Several other
studies have also documented the unique ability of Lb
Isolated bacteria:             Synbiotic Fibres only
Enterococcus faecalis
Escherichia coli
Enterobacter cloacae 0                 2
Pseudomonas aeruginosa
Staphylococcus aureus 0 1 





Figure 1 Isolated bacteria in acute pancreatitis treated with
Synbiotic 2000 or Only the fibres.
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duction of suppressive cytokines as TGFβ and Il-10, sup-
press CD4 T-cells, suppress Th2 activity, suppress
splenocyte proliferation and decrease antigen-specific
IgE and IgG1 [50-53].
The effect of Lactobacillus paracasei (NCC 2461),
Lactobacillus johnsonii (NCC 533) and Bifidobacterium
lactis Bb12 (NCC 362) on the induction and mainten-
ance of oral tolerance to bovine beta-lactoglobulin (BLG)
was investigated in mono-colonized germfree mice. The
effects of L. paracasei were reported superior to those of
the other two [53]. A study, which compared the ability
of 50 different LAB to control 23 different pathogenic
Clostridium difficile found more than half (27/50) totally
ineffective, (18/50) antagonistic to some , but only five
strains effective against all: two strains of Lb paracasei s.
paracasei and five strains of Lp plantarum [54]. Another
study compared the effects in rats receiving during days
10 to 21 after Trichinella spiralis - induced infection ei-
ther Lactobacillus paracasei, Lactobacillus johnsonii,
Bifidobacterium longum, or Bifidobacterium lactis; Lb
paracasei but not the other LAB attenuated muscle
hyper-contractility, reduced the infection-associated Th-
2 response and muscle levels of TGF-β, COX-2 and
PGE2 [55]. A recent study compared in animals the
effects of three probiotic strains: Bifidobacterium lactis
NCC362, Lactobacillus johnsonii NCC533, and Lactoba-
cillus paracasei NCC2461 on stress-induced changes in
gut permeability & on sensitivity to colorectal distension
(CRD) Only Lb paracasei both prevented reduced signifi-
cantly existing visceral pain and also restored normal gut
permeability [56].
Synbiotic 2000 in clinical medicine
I have dedicated most of my clinical research during the
last two decades to studies on effects of synbiotic com-
positions in various clinical situations, during the 1990s
to the monostrain/monofibre composition, mentioned
above, and 2000s to the multistrain/multifibre compos-
ition, also mentioned above; Synbiotic 2000 and 2000
Forte res. Here follows a summary of the effects
observed this far. It has been tried in the following
conditions:
Acute pancreatitis
Sixty-two patients with severe acute pancreatitis (SAP)
(Apache II scores: Synbiotic 2000-treated 11.7 ± 1.9, con-
trols 10.4 ± 1.5) were given either two sachets/day of Syn-
biotic 2000™ (2x40 billion LAB/day and totally 20 g
fibres) or the same amounts of fibres in (20 g) as in Syn-
biotic 2000™ during the first 14 days after arrival to the
hospital [57]. 9/33 patients (27%) in the Synbiotic 2000-
treated group and 15/29 patients (52%) in the only fibre-
treated group developed subsequent infections. 8/33(24%) Synbiotic 2000-treated and 14/29 (48%) of the only
fibre-treated patients developed SIRS, MOF or both (p
< 0.005). A total of pathogenic microorganisms of seven
were cultivated in the Synbiotic treated group compared
to seventeen in the fibre-only group (Figure 1).Polytrauma Two prospective randomized trials one with
Synbiotic 2000 and one with Synbiotic 2000 Forte re-
spectively have been concluded. The first study com-
pared in patients with acute extensive trauma: 1.
Synbiotic 2000 (40 billion LAB/d) with 2. a soluble fibre
3. a peptide diet (Nutricomp, Braun Inc Germany) and 4.
supplementation of glutamine. Treatment with Synbiotic
2000™ lead to a highly significant decrease in number of
chest infections (4/26 patients - 15%), compared to pep-
tide diet (11/26 patients - 42%, p< 0.04), glutamine (11/
32 patients - 34%, p< 0.03) and only fibres (12/29
patients- 41%, p< 0.002) [58]. Also the total number of
infections were significantly decreased; Synbiotic 2000™
5/26 patients (19%) only fibres 17/29 patients (59%) pep-
tide 13/26 patients (50%) and glutamine16/32 patients
(50%).
In the second study sixty-five patients polytrauma
patients were randomized to receive once daily for 15 d
Synbiotic 2000 Forte (400 billion LAB+ 10 gram of
fibres, see above) or maltodextrine as placebo. Significant
reductions were observed in number of deaths (5/35 vs
9/30, p< 0,02), severe sepsis (5/35 vs 13/30, p< 0.02),
chest infections (19/35 vs 24/30, p< 0.03), central line
infections (13/32 vs 20/30, p< 0.02), and ventilation days
(average 15 vs 26 days) [59]. A total of pathogenic micro-
organisms of 54 were cultivated in the Synbiotic treated
group compared to 103 in the placebo group. The time
to progression to primary bacteraemia was longer among
patients treated with Synbiotic 2000 Forte compared
with placebo (p _ 0.0237 between groups). Twelve
(33.3%) and five (13.9%) placebo-treated and synbiotic-
treated patients, respectively, developed ventilator-asso-
ciated pneumonia with Acinetobacter baumannii as a
bacterial cause (p 0.047 between groups). Treatment with
Synbiotic 2000 Forte was accompanied by reduction of
white blood cell counts and LPS and CRP levels in either
patients who did or did not develop sepsis [60].
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forty-five patients undergoing major surgery for abdom-
inal cancer were divided into three treatment groups: 1.
enteral nutrition (EN) + Synbiotic 2000 (LEN), 2. EN+
only the fibres in the same amounts (20 g) (20 g) as in
Synbiotic 2000™ (FEN) and 3. A standard parenteral nu-
trition (PN). All treatments lasted for 2 preoperative and
7 days postoperative days. The incidence of postoperative
bacterial infections was 47% with PN, 20% with FEN and
6.7% with LEN (p< 0.05) (Han Chun Mao et al in press).
A total of pathogenic microorganisms of 34 were culti-
vated in the Synbiotic treated group compared to 54 in
the fibre-only group. Significant improvements were also
documented in prealbumin (LEN, FEN), C-reactive pro-
tein (LEN, FEN), serum cholesterol (LEN,FEN), white
cell blood count (LEN) , serum endotoxin (LEN, FEN)
and IgA (LEN). In another prospective randomized
double-blind trial performed in 80 patients subjected to
pylorus-preserving pancreatoduodenectomy (PPPD) re-
ceive twice daily either Synbiotic 2000TM (2x40 billion
LAB) or only the fibres in composition from the day be-
fore surgery and during the first seven postoperative days
[61]. A highly significant difference in infection rate
(p= 0,005) was observed as only 5/40 patients (12.5%) in
the Synbiotic 2000-treated group suffered infections (4
wound and one urinary tract infection) versus 16/40
(40%) in the Only fibre group (6 wound infections, 5
peritonitis, 4 chest infections, 2 sepsis, and one of each
of urinary tract infection, cholangitis and empyema). The
infecting microorganism were in the Synbiotic treated
group Klebsiella pneumoniae (2 patients), Enterobacter
cloacae (2 patients), Proteus mirabilis (1 patient) and En-
terococcus faecalis/faecium (1 patient) and in the Only
fibre group Enterobacter cloacae (8 patients), Entero-
coccus faecalis/faecium (7 patient), Escherichia coli (7 pa-
tient), Klebsiella pneumoniae (2 patients), Staphylococcus
aureus (2 patients), and Proteus mirabilis (1 patient) -
see further Figure 2. Statistically significant differences
between the groups were also observed in use of antibio-
tics (mean: Synbiotic 2000; 2 ± 5 days, Only fibres;
10 ± 14 days).• Isolated bacteria      Synbiotic 2000  Fibres only
• Enterobacter cloacae                  2             8
• Enterococcus faecalis/faecium   1             7
• Escherichia coli                           0            7
• Klebsiella pneumoniae                2            2
• Proteus mirabilis                         1            1
• Staphylococcus aureus               0            2
Total 6 27
Figure 2 Isolated bacteria in patients undergoing
pancreatoduodenectomy and treated with Synbiotic 2000 or
Only the fibres.Chronic liver disease and liver transplantation Fifty-
eight patients with liver cirrhosis suffering so called minimal
encephalopathy were randomized into three treatment
groups: Group 1 (20 patients) received Synbiotic 2000 (40
billion LAB), group 2. (20 patients) received the same
amount of the fibres in Synbiotic 2000 and group 3. (15
patients) received placebo (non-fermentable, non-absorb-
able fibre -crystalline cellulose) [62]. A significant increase
in intestinal LAB flora was observed after one month of
supplementation in the Synbiotic-treated group, but not in
the other two groups. Intestinal pH was significantly
reduced in both treatment groups but not in the placebo-
treated group. Significant decreases in faecal counts of
Escherichia coli, Staphylococcus and Fusobacterium, but not
in Pseudomonas and Enterococcus, and significant decreases
in ammonia/s, endotoxin/s ALT/s and bilirubin/s (original
level 252±182) were observed in the Synbiotic 2000-treated
group ( 84±65, p< 0.01) and in the Only fibre-treated
group (110±86, p< 0.05) while it remained unchanged in
the placebo group. The improvements in liver function
were accompanied by significant improvements in psycho-
metric tests and in degree of encephalopathy.
In a follow-up study by the same group of investigators
30 patients with liver cirrhosis were randomized to re-
ceive either Synbiotic 2000 or placebo (crystalline cellu-
lose ) for 7 days [63]. Viable fecal counts of Lactobacillus
species, Child-Pugh class, plasma retention rate of indo-
cyanine green (ICGR15), whole blood tumour necrosis
factor alpha (TNF–6 (IL-6) mRNA, serum TNF-α, sol-
uble TNFreceptor (sTNFR)I, sTNFRII and IL-6 and
plasma endotoxin levels were measured pre- and post-
treatment: Synbiotic treatment was associated with sig-
nificantly increased faecal lactobacilli counts and signifi-
cant improvements in plasma retention rate of
indocyanine green (ICGR15) and stage of liver disease
(Child-Pugh classification). No significant changes in any
study parameter followed placebo treatment, but signifi-
cant increases in whole blood whole blood tumour ne-
crosis factor alpha (TNF- α) mRNA and interleukin-6
(IL-6) mRNA, along with serum levels of soluble TNF
receptors sTNFRI and sTNFRII, were observed in the
Synbiotic 2000-treated patients. TNF- α and IL-6 levels
correlated significantly, both at baseline and post-synbio-
tic treatment. Synbiotic-related improvement in ICGR15
was significantly associated with changes in IL-6, both at
mRNA and protein levels, and unrelated to plasma endo-
toxin values. It was concluded that even short-term syn-
biotic treatment can significantly modulates gut flora
and improve liver function in patients with cirrhosis.
The observed benefits seemed unrelated to reduction in
endo-toxaemia, but could be mediated, at least in part,
by treatment-related induction of IL-6 synthesis by TNF-
α. These results offers great hope that synbiotic treat-
ment to patients on waiting list for liver transplantation
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and promote successful outcome of surgery.
Sixty-six patients were randomized to either receive
Synbiotic 2000 or only the fibres in Synbiotic 2000 in
connection with human ortotopic liver transplantation.
The treatment started already on the day before surgery
and continued for 14 days after surgery. During the first
postoperative month did only one patient in the Synbio-
tic 2000-treated group (3%) show signs of infection
(urinary infection) compared to 17/33 (51%) in the
patients supplemented with only the four fibers [64]. The
infecting organisms were in the Synbiotic-treated group
Enterococcus fecalis in 1 patient and in the only fibre-
treated group Enterococcus fecalis/fecium 11, Escherichia
coli 3, Enterobacter cloacae 2, Pseudomonas aeruginosa 2
and Staphylococcus aureus in 1 patient, see further Fig-
ure 3. The use of antibiotics was in average 0.1 ± 0.1 d in
the synbiotic-treated patients and 3.8 ± 0.9 d in the only
fibre-treated group.
Inflammatory bowel disease Daily rectal instillations
with Synbiotic 2000 reconstituted in saline were given to
ten patients with distal colitis during 2 weeks. One pa-
tient withdraw after one week, the remaining patients
showed during the 3 weeks of observation dramatic
improvements in various disease scores; episodes of diar-
rhoea ((2.4⇒ 0.8), visible blood in stool (2.2⇒ 0.8),
nightly diarrhoea (0.5⇒ 0), urgency (1.9⇒ 1.0) and
consistency of stool ((1.1⇒ 0.8) [65]. Two patients
reported significant bloating and wind but no other ad-
verse or side effects were reported.
Treatment-resistant conditions
Treatment with synbiotics have not this far improved the
disease in two groups of conditions:
Inflammatory bowel disease - Crohn’s Disease (CD):
Sixty-three patients were after an initial treatment with
infliximab randomized to daily receive either Synbiotic
2000 or crystalline cellulose as placebo [66]. Median
time to relapse was 9.8 and 10.1 months respectively. In
a second study were following surgery patients









Staphylococcus aureus 0 1 
Total 1        18
Figure 3 Isolated bacteria in patients undergoing liver
transplantation and treated with Synbiotic 2000 or Only the
fibres.cellulose as placebo. Seven patients in the synbiotic-
treated group and two in the placebo group completed
the scheduled 24 month treatment [67]. No differences
were observed between the two groups either in
endoscopic findings or rate of clinical relapse. The so
called Rutgeerts disease scores were after three months
of treatment 0.6 ± 0.8 in the synbiotic-treated group and
0.8 ± 1 in the placebo group (NS).
General intensive care patients: Two large studies have
been performed in a general intensive care population;
one with Synbiotic 2000 and one with Synbiotic 2000
FORTE. Synbiotic 2000 (40 billion LAB) was given to
162 patients and only fibre the fibres in the synbiotic
composition to 168 patients. No difference was
observed in mortality or in multi-organ dysfunction
[68]. In another study Synbiotic 2000 FORTE 130
patients were supplemented twice a day throughout the
whole ICU stay to (2 × 400 billion LAB) and compared
to 129 patients supplemented a cellulose based placebo.
No statistical difference was demonstrated between the
groups in the incidence of VAP (9 and 13%, P= 0.31).
The rate of ventilator-associated pneumonia (VAP) per
1000 ventilator days was 13 and 14.6 (p= 0.73) and
hospital mortality 27 and 33%, (p= 0.32), respectively
[69].
Conclusions
Thousands of factors are important to maintain health
and to cure disease. This might explain why single drug
pharmacy fails, both to prevent disease and to cure dis-
ease especially when chronic. Human innate immunity is
for a proper function much depending on continuous ac-
cess to bacteria and plants. Using probiotics in combin-
ation with plants and their active ingredients remains an
attractive approach for prevention and treatment of vari-
ous both acute and chronic diseases. Ten year old studies
in the United States demonstrate an 83 percent reduc-
tion in rate of coronary heart disease [70], a 91 percent
reduction in diabetes in women [71], and a 71 percent
reduction in colon cancer in men [72] in patients adher-
ing to what is regarded as an “healthy lifestyle”: no use of
tobacco, moderate use of alcohol, regular physical exer-
cise, and eating a diet low in animal fat, low in refined
carbohydrates, and rich in fresh fruits and vegetables (if
raw also rich in lactic acid bacteria) and fish, a diet often
referred to as Mediterranean diet.
Crohn’s disease, as an example, has despite vigorous
attempts over the years remained most resistant to ther-
apy, pharmaceutical as well as probiotic treatments -see
recent review [73]. Solid observations suggest that sev-
eral Th1-mediated autoimmune diseases, such as mul-
tiple sclerosis, type 1 diabetes, rheumatoid arthritis and
Crohn´s disease are associated with low vitamin D sta-
tus, and a recent study demonstrates strong molecular
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Crohn’s disease [74]. Crohn’s disease is also strongly
associated with lack of minerals, especially calcium and
magnesium. Hypomagnesaemia is known to be strongly
associated with increased systemic inflammation, mani-
festing in leukocyte and macrophage activation and
increased production of inflammatory cytokines and
acute phase proteins. A recent study demonstrated a
much deranged microbionta in experimental animals
with induced hypomagnesemia [75]. It is certainly too
much to request that pre-, pro-, or synbiotics shall make
a difference in such conditions unless the underlying
defects in metabolism and immune functions are
corrected.
Inflammation is “the mother of disease” and much
associated with the food we eat [76,77]. As pointed out
above, numerous factors contribute to the deranged in-
nate immune system and the sustained exaggerated in-
flammation. Numerous changes are also required to
permanently control the hyper-inflammation and subse-
quent disease. Supply of pre-, pre-, and synbiotics are
strong tools for such corrections of immune functions
and resistance to disease. However, in most instances
also other measures are necessary, including reduction
in intake of pro-inflammatory molecules [2,78], and also
substantial intake of anti-inflammatory food ingredients
such as turmeric/curcumin [79,80].
The critical care units constitute a highly artificial
environment and the burden of environment-induced
physical and mental stress and subsequent status of
systemic hyper-inflammation on the patient is un-
bearable. Patients treated under these conditions are
in many aspects dys-functional, the whole microbiota
is more or less gone and probiotic bacteria supplied
will most often be killed already before they have
reached the lower gastro-intestinal tract. The degree
of artificiality seems to vary from hospital to hospital
and from country to country, which might explain
the great variation in outcome from studies under-
taken in different regions and countries.
Probiotic treatment has never been given the
chance as an alternative treatment, it has only this
far been tried as a treatment complementary to all
the other standard treatments. As discussed above, a
series of auxiliary measures and particularly mechan-
ical ventilation and treatment with various drugs, in-
cluding antibiotics but also clinical nutrition
solutions belong to those factors which promote
super-inflammation and indirectly infection. Enteral
nutrition formulas are also known to induce loss of
intestinal barrier function, promotes bacterial trans-
location, and impair host immune defense, a
phenomenon, observed in humans and further eluci-
dated in animal studies.Competing interests
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